Targeting the hedgehog signaling pathway with interacting peptides to Patched-1

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Aberrant activation of the hedgehog (Hh) signaling pathway is a hallmark of many cancers.
• Sonic hedgehog (Shh) ligand overproduction inhibits Patched-1 (Ptch1), a tumor suppressor, thereby increasing Hh pathway activity.
• Pancreatic cancer and other Hh-dependent malignancies represent significant therapeutic challenges.

Purpose of the Study:

• To develop a novel therapeutic strategy for pancreatic and other Hh-dependent cancers.
• To investigate the potential of controlling the tumor-suppressive function of Patched-1 (Ptch1).
• To identify peptides that interact with the Shh-binding site on Ptch1.

Main Methods:

• Synthesis of seven peptides designed to interact with the Ptch1-Shh docking site.
• In vitro assessment of peptide effects on human pancreatic cancer cell lines (AsPC-1, SUIT2) using cell counting and MTT assays.
• In vivo evaluation of peptide anti-tumor activity in a mouse model of pancreatic cancer, including Gli1 expression analysis.

Main Results:

• Three synthesized peptides significantly suppressed pancreatic cancer cell proliferation in vitro.
• These peptides reduced Gli1 gene expression, a marker of Hh pathway activity, in both in vitro and in vivo models.
• Demonstrated in vivo anti-tumor efficacy in a pancreatic cancer mouse xenograft model.

Conclusions:

• Interacting peptides targeting Ptch1 represent a potential new therapeutic approach for pancreatic cancer.
• These peptides offer a novel strategy for modulating the Hh signaling pathway in cancer treatment.
• Further development of Ptch1-interacting peptides could lead to effective therapies for Hh-dependent cancers.